Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.

Kato I, Nishinaka Y, Nakamura M, Akarca AU, Niwa A, Ozawa H, Yoshida K, Mori M, Wang D, Morita M, Ueno H, Shiozawa Y, Shiraishi Y, Miyano S, Gupta R, Umeda K, Watanabe K, Koh K, Adachi S, Heike T, Saito MK, Sanada M, Ogawa S, Marafioti T, Watanabe A, Nakahata T, Enver T.

Blood. 2017 Jun 8;129(23):3126-3129. doi: 10.1182/blood-2016-06-721712. Epub 2017 Apr 19. No abstract available.

2.

Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia.

Morita M, Nishinaka Y, Kato I, Saida S, Hiramatsu H, Kamikubo Y, Heike T, Nakahata T, Adachi S.

Int J Hematol. 2017 Mar;105(3):335-340. doi: 10.1007/s12185-016-2137-5. Epub 2016 Nov 15.

PMID:
27848186
3.

Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1.

Nagamori S, Wiriyasermkul P, Guarch ME, Okuyama H, Nakagomi S, Tadagaki K, Nishinaka Y, Bodoy S, Takafuji K, Okuda S, Kurokawa J, Ohgaki R, Nunes V, Palacín M, Kanai Y.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80. doi: 10.1073/pnas.1519959113. Epub 2016 Jan 6.

4.

In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.

Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, Ebihara Y, Ma F, Matsuda K, Saito S, Hirabayashi K, Kurata T, Uyen LT, Nakazawa Y, Tsuji K, Heike T, Nakahata T, Koike K.

Leukemia. 2015 Mar;29(3):606-14. doi: 10.1038/leu.2014.239. Epub 2014 Aug 8.

PMID:
25102944
5.

Uric acid induces NADPH oxidase-independent neutrophil extracellular trap formation.

Arai Y, Nishinaka Y, Arai T, Morita M, Mizugishi K, Adachi S, Takaori-Kondo A, Watanabe T, Yamashita K.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):556-61. doi: 10.1016/j.bbrc.2013.12.007. Epub 2013 Dec 8.

PMID:
24326071
6.

Establishment of stable cell lines with high expression of heterodimers of human 4F2hc and human amino acid transporter LAT1 or LAT2 and delineation of their differential interaction with α-alkyl moieties.

Khunweeraphong N, Nagamori S, Wiriyasermkul P, Nishinaka Y, Wongthai P, Ohgaki R, Tanaka H, Tominaga H, Sakurai H, Kanai Y.

J Pharmacol Sci. 2012;119(4):368-80. Epub 2012 Jul 31.

7.

Identification of hepatic niche harboring human acute lymphoblastic leukemic cells via the SDF-1/CXCR4 axis.

Kato I, Niwa A, Heike T, Fujino H, Saito MK, Umeda K, Hiramatsu H, Ito M, Morita M, Nishinaka Y, Adachi S, Ishikawa F, Nakahata T.

PLoS One. 2011;6(11):e27042. doi: 10.1371/journal.pone.0027042. Epub 2011 Nov 1.

8.

Singlet oxygen is essential for neutrophil extracellular trap formation.

Nishinaka Y, Arai T, Adachi S, Takaori-Kondo A, Yamashita K.

Biochem Biophys Res Commun. 2011 Sep 16;413(1):75-9. doi: 10.1016/j.bbrc.2011.08.052. Epub 2011 Aug 18.

PMID:
21871447
9.

Substituent effects of pterin derivatives on singlet oxygen scavenging activity.

Mori H, Nishinaka Y, Nonogawa M, Sommani P, Makino K, Yamashita K, Arai T.

Biol Pharm Bull. 2010;33(5):905-8.

10.

Edaravone directly reacts with singlet oxygen and protects cells from attack.

Nishinaka Y, Mori H, Endo N, Miyoshi T, Yamashita K, Adachi S, Arai T.

Life Sci. 2010 May 22;86(21-22):808-13. doi: 10.1016/j.lfs.2010.03.017. Epub 2010 Mar 27.

PMID:
20350554
11.

Alpha-phenyl-N-tert-butyl nitrone has scavenging activity against singlet oxygen ((1)O(2)) and attenuates (1)O(2)-induced neuronal cell death.

Kawai A, Nishinaka Y, Arai T, Hirota K, Mori H, Endo N, Miyoshi T, Yamashita K, Sasada M.

J Pharmacol Sci. 2008 Dec;108(4):545-9. Epub 2008 Dec 10.

12.

Effects of injectable propofol emulsion on singlet oxygen released from activated human neutrophils and that chemically generated.

Senda C, Nishinaka Y, Arai T, Segawa H, Mori H, Nonogawa M, Endo N, Miyoshi T, Yamashita K, Sasada M.

J Pharmacol Sci. 2008 Aug;107(4):460-4. Epub 2008 Aug 5.

13.

Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.

Ahsan MK, Masutani H, Yamaguchi Y, Kim YC, Nosaka K, Matsuoka M, Nishinaka Y, Maeda M, Yodoi J.

Oncogene. 2006 Apr 6;25(15):2181-91.

PMID:
16314839
14.

Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis.

Dutta KK, Nishinaka Y, Masutani H, Akatsuka S, Aung TT, Shirase T, Lee WH, Yamada Y, Hiai H, Yodoi J, Toyokuni S.

Lab Invest. 2005 Jun;85(6):798-807.

15.

Selective neuronal vulnerability and inadequate stress response in superoxide dismutase mutant mice.

Lynn S, Huang EJ, Elchuri S, Naeemuddin M, Nishinaka Y, Yodoi J, Ferriero DM, Epstein CJ, Huang TT.

Free Radic Biol Med. 2005 Mar 15;38(6):817-28.

PMID:
15721992
16.

Regulation of human osteoclast differentiation by thioredoxin binding protein-2 and redox-sensitive signaling.

Aitken CJ, Hodge JM, Nishinaka Y, Vaughan T, Yodoi J, Day CJ, Morrison NA, Nicholson GC.

J Bone Miner Res. 2004 Dec;19(12):2057-64. Epub 2004 Sep 20.

17.

Importin alpha1 (Rch1) mediates nuclear translocation of thioredoxin-binding protein-2/vitamin D(3)-up-regulated protein 1.

Nishinaka Y, Masutani H, Oka S, Matsuo Y, Yamaguchi Y, Nishio K, Ishii Y, Yodoi J.

J Biol Chem. 2004 Sep 3;279(36):37559-65. Epub 2004 Jul 2.

18.

Cysteine-dependent immune regulation by TRX and MIF/GIF family proteins.

Kondo N, Ishii Y, Son A, Sakakura-Nishiyama J, Kwon YW, Tanito M, Nishinaka Y, Matsuo Y, Nakayama T, Taniguchi M, Yodoi J.

Immunol Lett. 2004 Mar 29;92(1-2):143-7.

PMID:
15081538
19.

Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation: implications for adult T-cell leukemia leukemogenesis.

Nishinaka Y, Nishiyama A, Masutani H, Oka S, Ahsan KM, Nakayama Y, Ishii Y, Nakamura H, Maeda M, Yodoi J.

Cancer Res. 2004 Feb 15;64(4):1287-92.

20.

TMX, a human transmembrane oxidoreductase of the thioredoxin family: the possible role in disulfide-linked protein folding in the endoplasmic reticulum.

Matsuo Y, Nishinaka Y, Suzuki S, Kojima M, Kizaka-Kondoh S, Kondo N, Son A, Sakakura-Nishiyama J, Yamaguchi Y, Masutani H, Ishii Y, Yodoi J.

Arch Biochem Biophys. 2004 Mar 1;423(1):81-7.

PMID:
14871470
21.

Redox-sensing release of human thioredoxin from T lymphocytes with negative feedback loops.

Kondo N, Ishii Y, Kwon YW, Tanito M, Horita H, Nishinaka Y, Nakamura H, Yodoi J.

J Immunol. 2004 Jan 1;172(1):442-8.

22.

Thioredoxin cytokine action.

Nishinaka Y, Nakamura H, Yodoi J.

Methods Enzymol. 2002;347:332-8. No abstract available.

PMID:
11898424
23.

Redox control of EBV infection: prevention by thiol-dependent modulation of functional CD21/EBV receptor expression.

Nishinaka Y, Nakamura H, Okada N, Okada H, Yodoi J.

Antioxid Redox Signal. 2001 Dec;3(6):1075-87.

PMID:
11813981
24.

Redox regulation by thioredoxin and thioredoxin-binding proteins.

Nishiyama A, Masutani H, Nakamura H, Nishinaka Y, Yodoi J.

IUBMB Life. 2001 Jul;52(1-2):29-33. Review.

25.

Regulatory roles of thioredoxin in oxidative stress-induced cellular responses.

Nishinaka Y, Masutani H, Nakamura H, Yodoi J.

Redox Rep. 2001;6(5):289-95. Review.

PMID:
11778846
26.

Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis.

Nakamura H, Herzenberg LA, Bai J, Araya S, Kondo N, Nishinaka Y, Herzenberg LA, Yodoi J.

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15143-8. Epub 2001 Dec 11.

27.

Redox control of cellular function by thioredoxin; a new therapeutic direction in host defence.

Nishinaka Y, Nakamura H, Masutani H, Yodoi J.

Arch Immunol Ther Exp (Warsz). 2001;49(4):285-92. Review.

PMID:
11726031
28.

Expression of thioredoxin and glutaredoxin, redox-regulating proteins, in pancreatic cancer.

Nakamura H, Bai J, Nishinaka Y, Ueda S, Sasada T, Ohshio G, Imamura M, Takabayashi A, Yamaoka Y, Yodoi J.

Cancer Detect Prev. 2000;24(1):53-60.

PMID:
10757123
30.

IgM anti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoma patients.

Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF.

J Invest Dermatol. 1999 Feb;112(2):205-9.

31.

Human IgM antibodies to tumor-associated gangliosides share VHIII (V3-23) and VKIV family subgroups.

Nishinaka Y, Hoon DS, Irie RF.

Immunogenetics. 1998 Jun;48(1):73-5. No abstract available.

PMID:
9601948
32.
33.

Development of a human monoclonal antibody to ganglioside G(M2) with potential for cancer treatment.

Nishinaka Y, Ravindranath MH, Irie RF.

Cancer Res. 1996 Dec 15;56(24):5666-71.

34.

Correlation between the exercise-induced increase in left ventricular filling pressure and the extent of ischemic or infarcted myocardium.

Ando A, Yokota M, Sobue T, Nishinaka Y, Iwase M, Hayashi H, Saito H.

Jpn Circ J. 1995 Nov;59(11):705-14.

PMID:
8747760
35.
36.

Hemodynamic effects of the calcium channel blocker pranidipine on exercise-induced angina.

Nishinaka Y, Yokota M, Watanabe M, Sobue T, Iwase M, Ukai M, Ando A, Nagata K, Saito H.

Int J Clin Pharmacol Ther. 1994 Oct;32(10):542-9.

PMID:
7834162
37.

[Free radical].

Nishinaka Y, Yokota M.

Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):196-200. Review. Japanese. No abstract available.

PMID:
12436527
38.

[Myocardial metabolism during dynamic exercise].

Sato K, Nishinaka Y, Morishita Y, Nakane K, Fukatsu T, Yokota M, Nakashima N.

Rinsho Byori. 1993 Sep;41(9):1043-8. Japanese.

PMID:
8254967
39.

A new sensitive chemiluminescence probe, L-012, for measuring the production of superoxide anion by cells.

Nishinaka Y, Aramaki Y, Yoshida H, Masuya H, Sugawara T, Ichimori Y.

Biochem Biophys Res Commun. 1993 Jun 15;193(2):554-9.

PMID:
8390246
40.

Abnormal postexercise systolic blood pressure response is a good indicator of impaired left ventricular filling during supine cycle ergometer exercise in patients with coronary artery disease.

Miyahara T, Yokota M, Sobue T, Nishinaka Y, Iwase M, Ukai M, Watanabe M, Kodama Y, Matsunami T, Koide M, et al.

Jpn Circ J. 1993 Jun;57(6):480-8.

PMID:
8340994
41.

Protective effect of FK506 on ischemia/reperfusion-induced myocardial damage in canine heart.

Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T.

J Cardiovasc Pharmacol. 1993 Mar;21(3):448-54.

PMID:
7681507
42.

Hemodynamic mechanisms of the antianginal action of a novel vasodilator FK409 in dynamic exercise-induced angina.

Yokota M, Matsunami T, Kodama Y, Sobue T, Nishinaka Y, Iwase M, Miyahara T, Koide M, Saito H, Shibata S.

J Cardiovasc Pharmacol. 1993 Mar;21(3):412-22.

PMID:
7681502
43.

[Impairment of radical scavenge system induced by ischemia-reperfusion].

Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T.

Jpn Circ J. 1993;57 Suppl 4:1341-3. Japanese. No abstract available.

PMID:
7966982
44.

The effects of a high dose of ascorbate on ischemia-reperfusion-induced mitochondrial dysfunction in canine hearts.

Nishinaka Y, Sugiyama S, Yokota M, Saito H, Ozawa T.

Heart Vessels. 1992;7(1):18-23.

PMID:
1583008
45.

The cardioprotective effect of gamma-glutamylcysteine ethyl ester during coronary reperfusion in canine hearts.

Nishinaka Y, Kitahara S, Sugiyama S, Yokota M, Saito H, Ozawa T.

Br J Pharmacol. 1991 Dec;104(4):805-10.

Supplemental Content

Loading ...
Support Center